Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Glucose Metabolism Disorders: early-phase trial registry
9 of 15 indexed Glucose Metabolism Disorders trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 9 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Glucose Metabolism Disorders: 15 US clinical trials tracked, 9 recruiting.
Glucose Metabolism Disorders is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 9 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Jaeb Center for Health Research, running 2 of these trials.
Enrollment posture brief
Registry condition glucose-metabolism-disorders
OPEN 9 | RECR 60% | LATE 0 | EARLY 5 | RANK #1140 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Abuse, Drug (60% recruiting · 5 trials)
Glucose Metabolism Disorders lists 9 open slots (60% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Glucose Metabolism Disorders on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Glucose Metabolism Disorders is recruiting above its size-band peers.
9 of 15 indexed trials (60%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Glucose Metabolism Disorders trials is spread across many organizations.
Jaeb Center for Health Research accounts for 2 of 15 trials (13.3%). 12 distinct sponsors appear on at least one study for this condition label.
-
Most Glucose Metabolism Disorders trials plan to enrol fewer than 100 people.
Median target enrolment is 84 among the 15 trials that report a genuine target (sentinel values excluded). 9 of those (60%) plan for fewer than 100 participants.
-
Glucose Metabolism Disorders research is mostly interventional.
11 interventional and 4 observational studies make up this index (73.3% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
Rare and Atypical Diabetes Network
University of South Florida
NCT05544266
Cognitive-Behavioral Therapy and Exercise Training in Adolescents At-Risk for Type 2 Diabetes
Colorado State University
NCT05543083
Clinical Trial Assessing Human Placental Membrane Products and Standard of Care Versus Standard of Care in Nonhealing DFUs and VLUs
C5 Biomedical
NCT06674980
Animal and Plant Proteins and Glucose Metabolism
University of Missouri-Columbia
NCT03994367
Regulation of Endogenous Glucose Production by Central KATP Channels
Meredith Hawkins
NCT03540758
Food Orders on Blood Glucose and Fuel Use At Rest
Old Dominion University
NCT06763562
In-Person Lifestyle Program for Black Adolescent Girls at Risk for Type 2 Diabetes
Cornell University
NCT06557317
Inhaled Insulin vs Rapid-acting Injections for Post-meal Glucose Control in Women With Gestational Diabetes
Jaeb Center for Health Research
NCT06535789
Brain Metabolism Observed at 7 Tesla
University of Texas Southwestern Medical Center
NCT05085704
Study of Fat Tissue's Ability to Take up Sugar in the Obese Population
University of Missouri-Columbia
NCT02994459
Intestinal Metabolic Reprogramming as a Key Mechanism of Gastric Bypass in Humans
University of Pittsburgh
NCT02710370
Day and Night Closed-loop in Young People With Type 1 Diabetes
Jaeb Center for Health Research
NCT02925299
Single-Dose And Multiple-Dose Safety And Tolerability Study Of PF-04856883 In Type 2 Diabetic Adult Females
Pfizer
NCT01301456
Multiple Dose Safety Toelrability, Pharmacokinetics and Midazolam Interaction In Healthy Overweight And Obese Subjects
Pfizer
NCT01757756
Treatment Development of Triheptanoin (G1D)
Juan Pascual
NCT03041363
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Glucose Metabolism Disorders records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Glucose Metabolism Disorders trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Glucose Metabolism Disorders page
15 registered trials, 9 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 9 Glucose Metabolism Disorders trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Jaeb Center for Health Research sponsors the most Glucose Metabolism Disorders trials on record, review their full trial history before evaluating a specific study. See Jaeb Center for Health Research's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Glucose Metabolism Disorders condition card totals 15 registered trials; most-linked intervention PF-04856883; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.